Aharon Gal
Chief Strategy & Growth OfficerNovartis
PharmaceuticalsView Profile →Senior Vice President, Finance · Vertex Pharmaceuticals
Jonathan Poole is senior vice president of finance at Vertex Pharmaceuticals. His career combines investment banking and private equity with finance leadership at Shire, Genocea Biosciences and Evelo Biosciences.
Last reviewed: Nov 2, 2026
Senior Vice President, Finance
Vertex Pharmaceuticals
Last Reviewed: November 2, 2026
Jonathan Poole is senior vice president of finance at Vertex Pharmaceuticals. His career combines investment banking and private equity with finance leadership at Shire, Genocea Biosciences and Evelo Biosciences.
Poole began his career in the United Kingdom, working in investment banking at UBS Warburg and ING Barings. He also worked as an investment manager at Avanti Capital, a private equity firm.
He joined Shire in December 2006 and progressed through finance and strategic-planning positions. From May 2010 to June 2013, he was divisional CFO of Shire Human Genetic Therapies, the company’s rare-disease business. He subsequently became senior vice president of finance for pipeline and technical operations, supporting global business development, research and development, and technical operations.
Poole moved to Genocea Biosciences as CFO in April 2014. He remained there until March 2018, when he joined Evelo Biosciences as CFO, also serving as treasurer. He held that position until March 2020.
At Vertex, Poole leads finance support for corporate, commercial, research and development, manufacturing and other functions. His work includes supporting acquisitions and their integration. In August 2026, Vertex selected him to become executive vice president and CFO effective January 1, 2027; until that transition, he remains senior vice president of finance.
Poole joined Acadia Pharmaceuticals’ board and audit committee in March 2026. Earlier, he served on Codiak Biosciences’ board and chaired its audit committee from 2018 to 2020.
Poole holds a Bachelor of Science in biological sciences from Durham University and an MBA from London Business School.